In 2020, the race for the Covid-19 vaccine distorted investment inflows in the biotechnology sector. Back then, emerging biotech stocks tripled or more on hopes that they would come out with a vaccine. Buying interest in vaccine research resumed earlier this year when Covid variants emerged. Once again, markets did not learn their lesson from…